Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Completed × Malignant Disease × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1325 Breast Neoplasms 682 Carcinoma, Non-Small-Cell Lung 542 Neoplasm Metastasis 434 Lymphoma 432 Leukemia, Myeloid, Acute 425 Melanoma 399 Prostatic Neoplasms 376 Multiple Myeloma 362 Lymphoma, Non-Hodgkin 353 Ovarian Neoplasms 341 Colorectal Neoplasms 329 Pancreatic Neoplasms 327 Precursor Cell Lymphoblastic Leukemia-Lymphoma 326 Leukemia, Lymphocytic, Chronic, B-Cell 323 Leukemia 282 Lung Neoplasms 271 Glioblastoma 265 Unspecified Adult Solid Tumor, Protocol Specific 257 Recurrence 250 Lymphoma, Follicular 247 Lymphoma, Large B-Cell, Diffuse 244 Brain Neoplasms 232 Lymphoma, Mantle-Cell 209 Hodgkin Disease 191 Carcinoma, Renal Cell 191 Head and Neck Neoplasms 189 Myelodysplastic Syndromes 184 Glioma 171 Burkitt Lymphoma 171

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡